Literature DB >> 30974053

Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Cara B Pasquale1, Jeffrey Vietri2, Radmila Choate3, Angee McDaniel4, Reiko Sato2, Kimbal D Ford5, Elisha Malanga1, Barbara P Yawn1.   

Abstract

Community acquired pneumonia (CAP) carries high morbidity, mortality, and economic burden, which is even higher in adults diagnosed with chronic obstructive pulmonary disease (COPD). While several studies have assessed the clinical burden and mortality risk of CAP and COPD, very few studies focus on CAP burden from a COPD patient perspective. Individuals recently diagnosed with CAP and with pre-existing COPD were recruited through the COPD Foundation. The CAP Burden of Illness Questionnaire (CAP-BIQ), a content validated questionnaire assessing CAP symptomatology, duration of symptoms and CAP impact on work, activities and family, was administered at baseline and at 30-days follow-up. Of the 490 participants recruited, 481 had data sufficient for analysis. The prevalence of respiratory-related symptoms was very high (>90%) at the time of diagnosis with other generalized symptoms such as fatigue, trouble sleeping, headaches and confusion present in more than 60% of participants. Mean duration of symptoms varied from approximately 2 weeks for headaches and fever to more than a month for fatigue, wheezing, dyspnea, and cough. Employed participants missed an average of 21 days of work and those not employed missed 36 days of usual activities. Over 84% required help from family, friends or care givers. CAP is a serious and burdensome condition for people with COPD, a condition that can impair activities for weeks, frequently requires care from family or friends, and includes lingering symptoms. The patient-reported impact of CAP reported in this study underscores the need for prevention strategies in this population. JCOPDF
© 2019.

Entities:  

Keywords:  community acquired pneumonia; copd; patient reported outcomes; symptom burden; time to resolution

Year:  2019        PMID: 30974053      PMCID: PMC6596434          DOI: 10.15326/jcopdf.6.2.2018.0144

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN: 2372-952X


  6 in total

1.  SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19.

Authors:  Geidy E Serrano; Jessica E Walker; Cécilia Tremblay; Ignazio S Piras; Matthew J Huentelman; Christine M Belden; Danielle Goldfarb; David Shprecher; Alireza Atri; Charles H Adler; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Richard Caselli; Bryan K Woodruff; Chadwick F Haarer; Thomas Ruhlen; Maria Torres; Steve Nguyen; Dasan Schmitt; Steven Z Rapscak; Christian Bime; Joseph L Peters; Ellie Alevritis; Richard A Arce; Michael J Glass; Daisy Vargas; Lucia I Sue; Anthony J Intorcia; Courtney M Nelson; Javon Oliver; Aryck Russell; Katsuko E Suszczewicz; Claryssa I Borja; Madison P Cline; Spencer J Hemmingsen; Sanaria Qiji; Holly M Hobgood; Joseph P Mizgerd; Malaya K Sahoo; Haiyu Zhang; Daniel Solis; Thomas J Montine; Gerald J Berry; Eric M Reiman; Katharina Röltgen; Scott D Boyd; Benjamin A Pinsky; James L Zehnder; Pierre Talbot; Marc Desforges; Michael DeTure; Dennis W Dickson; Thomas G Beach
Journal:  J Neuropathol Exp Neurol       Date:  2022-08-16       Impact factor: 3.148

2.  A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP).

Authors:  Juan P Horcajada; Robert A Salata; Rodolfo Álvarez-Sala; Floarea Mimi Nitu; Laura Lawrence; Megan Quintas; Chun-Yen Cheng; Sue Cammarata
Journal:  Open Forum Infect Dis       Date:  2019-12-05       Impact factor: 3.835

Review 3.  Community-Acquired Bacterial Pneumonia-Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin.

Authors:  Roopali Sharma; Christian E Sandrock; Joni Meehan; Nicolette Theriault
Journal:  Clin Drug Investig       Date:  2020-10       Impact factor: 2.859

4.  Increased Risk of Autopsy-Proven Pneumonia with Sex, Season and Neurodegenerative Disease.

Authors:  Thomas G Beach; Aryck Russell; Lucia I Sue; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Richard Arce; Courtney M Nelson; Tony Hidalgo; Glenn Chiarolanza; Monica Mariner; Alex Scroggins; Joel Pullen; Leslie Souders; Kimberly Sivananthan; Niana Carter; Megan Saxon-LaBelle; Brittany Hoffman; Angelica Garcia; Michael Callan; Brandon E Fornwalt; Jeremiah Carew; Jessica Filon; Brett Cutler; Jaclyn Papa; Jasmine R Curry; Javon Oliver; David Shprecher; Alireza Atri; Christine Belden; Holly A Shill; Erika Driver-Dunckley; Shyamal H Mehta; Charles H Adler; Chadwick F Haarer; Thomas Ruhlen; Maria Torres; Steve Nguyen; Dasan Schmitt; Mary Fietz; Lih-Fen Lue; Douglas G Walker; Joseph P Mizgerd; Geidy E Serrano
Journal:  medRxiv       Date:  2021-01-08

5.  Acute Brain Ischemia, Infarction and Hemorrhage in Subjects Dying with or Without Autopsy-Proven Acute Pneumonia.

Authors:  Thomas G Beach; Lucia I Sue; Anthony J Intorcia; Michael J Glass; Jessica E Walker; Richard Arce; Courtney M Nelson; Geidy E Serrano
Journal:  medRxiv       Date:  2021-03-26

6.  Influence of Pneumonia on the Survival of Patients with COPD.

Authors:  Zichen Ji; Julio Hernández Vázquez; José María Bellón Cano; Virginia Gallo González; Beatriz Recio Moreno; Alicia Cerezo Lajas; Luis Puente Maestu; Javier de Miguel Díez
Journal:  J Clin Med       Date:  2020-01-15       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.